Important considerations for the referral of patients with severe aortic stenosis

Speaker: Dr. Shrilla Banerjee
Surrey and Sussex Healthcare NHS Trust

In this recorded webinar hear from leading cardiologist Dr. Shrilla Banerjee on:

  • What sort of service does she want for her patients
  • Which patients should be referred
  • The ideal patient pathway
  • Barriers to the adoption of TAVI
  • A new tool for the referral process that includes assessment of frailty

In the new publication from GIRFT (Get It Right First Time) “to ensure that serial referrals are avoided and that all relevant treatment options are considered, each tertiary centre should have a single point of entry into a pathway for the assessment of patients referred for consideration of intervention for severe aortic valve disease and another for the assessment of severe mitral/tricuspid disease. Referrals should be made to the relevant heart team rather than to an individual cardiologist or surgeon.1

Hear more from Dr. Shrilla Banerjee on her view of the perfect referral pathway.

More about the 2021 ESC/EACTS ESC Guidelines

Check our latest articles

View all articles

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more

References:

1 Clarke, S and Ray, S (2021) GIRFT Programme National Specialty Report, Cardiology pg 38. Available at: https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2021/02/Cardiology-10-03i-EMBARGOED.pdf

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-3409 v2.0